KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Basic) (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EPS (Basic) for 16 consecutive years, with $0.01 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 117.64% year-over-year to $0.01, compared with a TTM value of $0.02 through Sep 2025, up 198.99%, and an annual FY2024 reading of -$0.19, up 74.32% over the prior year.
  • EPS (Basic) was $0.01 for Q3 2025 at TherapeuticsMD, down from $0.05 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $22.94 in Q4 2022 and bottomed at -$10.26 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.54, with a median of -$0.11 recorded in 2021.
  • The sharpest move saw EPS (Basic) crashed 6740.0% in 2021, then soared 323.59% in 2022.
  • Year by year, EPS (Basic) stood at -$10.26 in 2021, then skyrocketed by 323.59% to $22.94 in 2022, then plummeted by 99.22% to $0.18 in 2023, then tumbled by 94.44% to $0.01 in 2024, then fell by 11.82% to $0.01 in 2025.
  • Business Quant data shows EPS (Basic) for TXMD at $0.01 in Q3 2025, $0.05 in Q2 2025, and -$0.06 in Q1 2025.